AroCell signs distribution agreement in Zambia and Malawi

AroCell continues to expand its business in Africa. Today, AroCell has signed a distribution agreement with MM African Technology covering Zambia and Malawi. The agreement covers the sale of TUBEX® TF and UBC® Rapid.

Since the launch in Africa, AroCell has focused on finding the right partners for distribution. The company has previously announced that agreements have been signed with distributors in Uganda, Ghana, and Kenya among others. AroCell has now signed a new distribution agreement with MM African Technology for distribution in Zambia and Malawi. The agreement covers the sale of the company's rapid test TUBEX® TF for typhoid fever and UBC® Rapid for detection of bladder cancer.

About AroCell

AroCell AB (publ) is a Swedish company that develops and markets blood and urine sample tests. The corporation specializes in oncology and bacteriology. The company has a broad product portfolio, used in healthcare, and established in various markets. In oncology, AroCell uses various biomarkers, TK1, and cytokeratins, to support the treatment of various cancers such as breast, prostate, and bladder cancers. AroCell's product portfolio also includes a rapid bacteriological test for a simple and safe diagnosis of typhoid fever. AroCell (AROC) is listed on Nasdaq First North Growth Market with Redeye AB as company's Certified Adviser. For more information; www.arocell.com